Table 3.
Correlation between expression of MMP-9 and clinicopathological parameters in Kazakh ESCCs
| Variable | Cases (N) | MMP9 low expression | MMP9 high expression | X2 | P |
|---|---|---|---|---|---|
|
|
|
||||
| 0/1+ (%) | 2+/3+ (%) | ||||
| Age (y) | |||||
| ≤58 | 53 | 25 (47.2%) | 28 (52.8%) | 1.273 | 0.259 |
| >58 | 47 | 19 (40.4%) | 28 (59.6%) | ||
| Gender | |||||
| Male | 70 | 29 (41.4%) | 41 (58.6%) | 0.333 | 0.564 |
| Femle | 30 | 12 (40.0%) | 18 (60.0%) | ||
| Tumor location | |||||
| Upper | 2 | 1 (50.0%) | 1 (50.0%) | / | 0.116 |
| Middle | 74 | 28 (37.8%) | 46 (62.2%) | ||
| Lower | 24 | 13 (54.2%) | 11 (45.8%) | ||
| Histologic grade | |||||
| Well | 29 | 5 (17.2%) | 24 (82.8%) | 1.009 | 0.605 |
| Moderate | 47 | 18 (38.3%) | 29 (61.7%) | ||
| Poor | 24 | 8 (33.3%) | 16 (66.7%) | ||
| Depth of invasion | |||||
| T1-T2 | 36 | 17 (47.2%) | 19 (52.8%) | 0.543 | 0.461 |
| T3-T4 | 64 | 24 (37.5%) | 40 (62.5%) | ||
| Nodal status | |||||
| pN- | 50 | 30 (60.0%) | 20 (40.0%) | 13.394 | <0.001* |
| pN+ | 50 | 11 (22.0%) | 39 (78.0%) | ||
| Clinical stage | |||||
| I-II | 62 | 34 (54.8%) | 28 (45.2%) | 11.455 | <0.001* |
| III-IV | 38 | 7 (18.4%) | 31 (81.6%) |
Note: pN-: no lymph node metastasis; pN+: node metastasis.
*
P<0.05.